Wednesday, July 8, 2026

Drug profile · INN

trientine tetrahydrochloride

trientine tetrahydrochloride (CUVRIOR) is a copper chelating agent. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — trientine tetrahydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

trientine tetrahydrochloride (CUVRIOR) is a copper chelating agent. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN trientine tetrahydrochloride
Brand CUVRIOR
Mechanism Copper chelating agent
Target Copper
Route ORAL
Formulation TABLET

Mechanism of action

Copper chelating agent

Primary target: Copper

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. penicillamine Copper chelating agent
  2. trientine hydrochloride Copper chelating agent
  3. abametapir Copper sequestering agent
  4. clioquinol Copper chelating agent
  5. trientine dihydrochloride Alimentary tract and metabolism (A16)

Frequently asked questions

What is trientine tetrahydrochloride?

trientine tetrahydrochloride (CUVRIOR) is a copper chelating agent. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for trientine tetrahydrochloride?

CUVRIOR is a marketed brand name for trientine tetrahydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of trientine tetrahydrochloride?

trientine tetrahydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.